MX2018013523A - Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. - Google Patents

Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.

Info

Publication number
MX2018013523A
MX2018013523A MX2018013523A MX2018013523A MX2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A MX 2018013523 A MX2018013523 A MX 2018013523A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
antibodies targeting
dna monoclonal
dna
composition
Prior art date
Application number
MX2018013523A
Other languages
English (en)
Inventor
Weiner David
Elliott Sarah
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018013523A publication Critical patent/MX2018013523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se describe en la presente una composicion que incluye una secuencia de acido nucleico recombinante que codifica un anticuerpo sintetico anti-IL-6 y/o anti-CD126; la descripción tambien proporciona un metodo para prevenir y/o tratar una enfermedad en un sujeto utilizando dicha composicion y metodo de generacion.
MX2018013523A 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a il-6 y cd126. MX2018013523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
MX2018013523A true MX2018013523A (es) 2019-06-10

Family

ID=60203626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013523A MX2018013523A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.

Country Status (12)

Country Link
US (1) US20190192692A1 (es)
EP (1) EP3452106A4 (es)
JP (2) JP7311113B2 (es)
KR (2) KR20230058733A (es)
CN (1) CN109789224A (es)
AU (1) AU2017261292A1 (es)
BR (1) BR112018072697A2 (es)
CA (1) CA3023089A1 (es)
EA (1) EA201892524A1 (es)
MX (1) MX2018013523A (es)
SG (2) SG10202011023YA (es)
WO (1) WO2017192933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
JP2024504614A (ja) * 2021-01-14 2024-02-01 トランスレイト バイオ， インコーポレイテッド ｍＲＮＡがコードする抗体を送達する方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528691A (ja) * 2001-11-14 2007-10-18 セントカー・インコーポレーテツド 抗ｉｌ−６抗体、組成物、方法および使用
CN101356194B (zh) * 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
WO2008019061A2 (en) * 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
EP2297202B1 (en) 2008-05-13 2016-01-13 NovImmune SA Anti-il-6/il-6r antibodies and methods of use thereof
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
KR20210088741A (ko) 2012-12-13 2021-07-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
EP3043774B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids

Also Published As

Publication number Publication date
EP3452106A1 (en) 2019-03-13
JP2023086734A (ja) 2023-06-22
JP2019518074A (ja) 2019-06-27
WO2017192933A1 (en) 2017-11-09
US20190192692A1 (en) 2019-06-27
JP7311113B2 (ja) 2023-07-19
EP3452106A4 (en) 2020-01-08
AU2017261292A1 (en) 2018-12-20
SG10202011023YA (en) 2020-12-30
SG11201809786TA (en) 2018-12-28
KR20190031439A (ko) 2019-03-26
CA3023089A1 (en) 2017-11-09
KR20230058733A (ko) 2023-05-03
CN109789224A (zh) 2019-05-21
BR112018072697A2 (pt) 2019-02-19
EA201892524A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
AR110321A1 (es) Anticuerpos antitau y métodos de uso
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MY184189A (en) Methods of treating nail and scalp psoriasis
EA202190807A1 (ru) Антитела к синуклеину
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MX2018013521A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
CR20210332A (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations